Safety Assessment of Hydrolyzed Wheat Protein and Hydrolyzed Wheat Gluten as Used in Cosmetics

Status: Tentative Report for Panel Review
Release Date: September 20, 2013
Panel Meeting Date: December 9-10, 2013

All interested persons are provided 60 days from the above release date to comment on this Safety Assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill.

The 2013 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, DPA. This report was prepared by Christina Burnett, Scientific Analyst/Writer, Bart Heldreth, Ph.D., Chemist CIR, and Ivan Boyer, Ph.D., Toxicologist CIR.
ABSTRACT
The Cosmetic Ingredient Review (CIR) Expert Panel reviewed the product use, formulation and safety data on hydrolyzed wheat protein and hydrolyzed wheat gluten, which function as skin and hair conditioning agents. The Panel determined that data on the elicitation of Type I hypersensitivity reactions in sensitized individuals were adequate to support the safety of these ingredients with peptide-length distributions not exceeding 30 amino acids. The Panel concluded that hydrolyzed wheat gluten and hydrolyzed wheat protein are safe in cosmetics when formulated to minimize peptide lengths greater than 30 amino acids. Additionally, these ingredients should not be used on damaged skin or in products that may contact mucous membranes or be incidentally inhaled.

INTRODUCTION
This safety assessment is of hydrolyzed wheat protein (HWP) and hydrolyzed wheat gluten, which are each mixtures of amino acids and peptides of varying length, derived from wheat sources. These ingredients function as skin and hair conditioning agents in personal care products. The CIR Panel (Panel) previously has reviewed the safety of \( \alpha \)-amino acids, animal- and plant-derived amino acids, hydrolyzed collagen, hydrolyzed corn protein, and Triticum Vulgare (wheat) gluten and concluded that these ingredients are safe for use in cosmetic ingredients.1-7

CHEMISTRY
The ingredients in this group are interrelated because they each are prepared from wheat proteins by partial hydrolysis to yield cosmetically acceptable raw materials. The definitions of these ingredients are presented in Table 1. Wheat gluten typically represents about 85% of wheat protein, and consists of the water-insoluble fraction of wheat proteins, including gliadins and glutenins.8 The remaining 15% of wheat proteins consists of water-soluble, non-gluten proteins, including albumins and globulins.

These protein derivatives are prepared by subjecting wheat proteins to enzymatic (e.g., papain hydrolysis) or other chemical hydrolyses (e.g., acid, alkaline, or steam hydrolysis). The resulting polypeptide-, oligopeptide-, and peptide-containing products are used as conditioning agents in hair and skin products. Methods used to manufacture protein hydrolysates typically yield broad molecular weight (MW) distributions of peptides, 500-30,000 daltons (Da); however, certain enzymes, such as papain, can routinely yield narrower distributions, 500-10,000 Da.9-11 For example, if the average molecular weight of an amino acid is 135 Da, then, under the broader distribution figures, these ingredients are approximately 4 to 220 amino acids in length (and approximately 4 to 74 amino acids in length under the narrower distribution).12

Method of Manufacturing
A supplier reported that HWP (MW = 350) may be prepared by both alkaline and enzyme hydrolysis.13 These processes occur for several hours until the desired molecular weight is reached. The final product is a 25% water solution of HWP. Summary information that includes this data along with additional data from other suppliers can be found in Table 2.

HWP contained in a facial soap that is associated with anaphylaxis reactions in Japan was produced from gluten by partial hydrolysis with hydrogen chloride at 95ºC for 40 min.14 The molecular weight of the main band of HWP as determined with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 40-50 kDa, which was larger than the main band in gluten.

Impurities
A supplier of HWP (MW = 350) reported levels of heavy metals and arsenic at < 5 ppm and 0.5 ppm, respectively.13

USE
Cosmetic
The HWP and hydrolyzed wheat gluten function primarily as hair conditioning agents and skin conditioning agents (miscellaneous) in cosmetic formulations.15 Additional functions may include film formers (HWP).

Table 3 presents the current product-formulation data for HWP and hydrolyzed wheat gluten. According to information supplied to the Food and Drug Administration (FDA) by industry as part of the Voluntary Cosmetic Registration Program (VCRP), HWP has the most reported uses in cosmetic and personal care products, with a total
of 1077; approximately half of those uses are in non-coloring hair products.\textsuperscript{16} Hydrolyzed wheat gluten has a total of 78 uses in cosmetic and personal care products with about half of the uses reported to be hair tints.

In the Personal Care Products Council’s (Council) use concentration survey, HWP had a wide maximum use concentration range of $2.0 \times 10^{-5}$ to 1.7%, with the 1.7% reported in rinse-off non-coloring hair products.\textsuperscript{17} Hydrolyzed wheat gluten had a maximum use concentration range of 0.005% to 0.09%, with 0.09% reported in eye makeup preparations.

HWP is used in cosmetic sprays, including aerosol and pump hair spray products, and could possibly be inhaled. The maximum concentration of HWP reported to be used in a spray product is 0.5% in a pump hair spray.

HWP and hydrolyzed wheat gluten are not restricted from use in any way under the rules governing cosmetic products in the European Union.\textsuperscript{18}

Non-Cosmetic

The FDA determined that the use of peptones as direct food substances is generally recognized as safe (GRAS). These GRAS peptones are defined as “the variable mixture of polypeptides, oligopeptides, and amino acids that are produced by partial hydrolysis of casein, animal tissue, soy protein isolate, gelatin, defatted fatty tissue, egg albumin, or lactalbumin (whey protein) (21 CFR §184.1553).

The FDA defines the term “protein” to mean any $\alpha$-amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size.\textsuperscript{19} The FDA considers a “peptide” to be any polymer composed of 40 or fewer amino acids.

The FDA requires allergen labeling when major allergens are included in food. The major allergens are milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans.\textsuperscript{20}

TOXICOKINETICS

No published toxicokinetics studies on HWP and hydrolyzed wheat gluten were identified by a literature search for these ingredients and no unpublished data were submitted.

TOXICOLOGICAL STUDIES

The proteins that serve as the sources of HWP and hydrolyzed gluten that are described in this safety assessment are found in the foods we consume daily. Toxicities from dermal exposure, other than irritation and sensitization, would not be expected to be different from oral exposures and as such not of concern by the Panel. Irritation and sensitization are of concern, and the focus in this report. Data from the previous safety assessment on $\alpha$-amino acids support that mixtures of amino acids would not likely be irritants or sensitizers.

GENOTOXICITY

No published genotoxicity studies on HWP and hydrolyzed wheat gluten were identified by a literature search for these ingredients and no unpublished data were submitted.

CARCINOGENICITY

No published carcinogenicity studies on HWP and hydrolyzed wheat gluten were identified by a literature search for these ingredients and no unpublished data were submitted.

IRRITATION AND SENSITIZATION

[From the CIR Safety Assessment of $\alpha$-amino acids]\textsuperscript{1}: Cysteine HCl and methionine were used as negative controls in in vitro assays to predict potential skin irritants. In separate efficacy studies, arginine, cysteine, and glycine did not produce any adverse effects in rats, guinea pigs, or mouse skin models. Glutamic acid was used as a negative control in an in vitro study to identify skin sensitizers. HRIPT studies of many products containing amino acid ingredients concluded that products containing these ingredients were not dermal irritants or sensitizers. In several validation studies for in vitro phototoxicity assays, histidine was used as a negative control. Magnesium aspartate up to 0.5% and 1% tyrosine were not phototoxic in assays using yeast.
Irritation

**Dermal – Non-Human**

In a primary dermal irritation study in 6 New Zealand white rabbits, acid- and enzyme-hydrolyzed HWP was not a primary skin irritant (primary skin irritation score = 0.50; a score of 5+ indicates a primary dermal irritant). The 25% aq. solution (MW = 350) was applied for 24 h to 2.5 cm² sites that were clipped, abraded, and occluded.

**Dermal - Human**

HWP was non-irritating in a human irritation patch test performed in 42 subjects. The HWP was tested at 25% aq. solution (MW = 350), and the subjects received a single dermal dose under occlusive conditions for 48 h.

**Ocular – Non-Human**

In an ocular irritation study in 6 albino rabbits, HWP (25% aq. solution, MW = 350) was not a primary eye irritant.

Sensitization

**Dermal - Non-Human**

The possibility of a transdermal pathway for sensitization to gluten and acid-hydrolyzed HWP was studied using BALB/c mice. The HWP was supplied by a manufacturer in Japan and was produced from gluten by partial hydrolysis with hydrogen chloride at 95º C for 40 min. The resultant HWP had a MW of approximately 40-50 kDa. The 7-week-old female mice were shaved and tape-striped 10 times to remove the stratum corneum, and were then exposed to HWP or gluten (500 µg/mouse) via transdermal patches for 3 to 4 cycles (each cycle consisting of 3 days with the patch on followed by 4 days without the patch), 3 days/week, with and without sodium dodecyl sulfate (SDS). Active systemic anaphylaxis (ASA) was then induced by intraperitoneal injection of HWP or gluten, respective of the material used during the transdermal exposure. Rectal temperature, scores of anaphylactic responses, and plasma histamine levels were measured. Dose-dependent production of IgE and IgG1 were observed. The i.p. injection of HWP caused ASA in the mice exposed transdermally to HWP, with decreased rectal temperatures, increased anaphylaxis scores, and increased plasma histamine levels. The i.p injection of gluten clearly induced ASA in the mice transdermally exposed to gluten in the presence of SDS, but not in the absence of SDS. When compared to the vehicle control group, the content of HWP-specific IgE and IgG1 were significantly increased in the HWP groups with and without SDS and in the gluten-with-SDS group; IgE in the gluten–without-SDS group was barely increased. The serum content of gluten-specific IgE was significantly increased in the gluten-with-SDS group and both HWP groups, but barely increased in the gluten-without-SDS group, when compared to the vehicle-control group. The serum content of gluten IgG1 with and without SDS and HWP without SDS were also significantly increased, but there were individual differences in the gluten-without-SDS group that showed that SDS had an important role in sensitization by transdermal exposure. Following elicitation of the immediate hypersensitivity reactions, harvested splenocytes were restimulated with HWP for 72 h. The secretion of IL-4, IL-5, and IL-10 was increased while that of IL-2 and interferon (FRN)-γ were significantly decreased, demonstrating that transdermal sensitization with HWP was associated with Th2-dominant helper T-cell activation.

**Dermal - Human**

In an occlusive human repeated insult patch test (HRIPT) of 52 subjects, no dermal irritation or sensitization was observed in response to HWP (25% aq. solution, MW = 350). A study of sensitization to protein hydrolysates in hair-care products was performed in 3 groups of patients. The first group, which consisted of 11 hairdressers with hand dermatitis, submitted to scratch and prick tests with 22 trademarked protein hydrolysates, including 2 HWP trademarked hydrolysates (specific chemical characteristics not provided). The second group was comprised of 2160 consecutive adults with suspected allergic respiratory disease: they were subjected to skin prick tests with hydroxypropyl trimonium hydrolyzed collagen, hydrolyzed collagen and/or hydrolyzed milk protein. The third group of 28 adult patients with atopic dermatitis was also tested with 1 to 3 of the hydrolysates tested in group 2 via a skin prick test. Positive reactions were seen in a total of 12 patients (all female with atopic dermatitis) to the hydroxypropyl trimonium hydrolyzed collagen, hydrolyzed collagen and/or hydrolyzed milk protein. No adverse reactions to the HWP trademarked hydrolysates were observed.
**Type 1 Hypersensitivity**

There have been several reports of Type 1 (i.e., immediate) hypersensitivity reactions to personal care products that contain HWP, as summarized below. An allergen must have at least 2 IgE epitopes, and each epitope must be at least 15 amino-acid residues long, to trigger a Type 1 hypersensitivity reaction. A patient becomes sensitized when two or more IgE molecules against a specific allergen are bound to receptors on the surface of a mast cell. The cross linking of two or more bound IgE molecules by the allergen results in degranulation of the mast cell and the release of vasoactive amines that elicit the Type I reaction.

The sera from 5 European patients were studied to determine the reactivity of IgE with hydrolyzed gluten. In 4 of the patients, immediate contact hypersensitivity to HWP (IHHWP) manifested as urticaria in response to either dermal contact with HWP (2 patients) or the ingestion of processed foods containing HWP (2 patients), without sensitivity to traditional wheat food products. The fifth patient (control) exhibited conventional wheat-dependent exercise-induced anaphylaxis (CO-WDEIA) in response to ingesting traditional wheat food products without exhibiting sensitivity to HWP.

The IgE reactivity of sera from the IHHWP patients and the CO-WDEIA patient was characterized using extracts of 4 hydrolyzed gluten preparations (enzymatically- or acid-hydrolyzed), total unmodified wheat protein (UWP), and UWP fractions (i.e., albumins/globulins, gliadins, and glutenins, including high-molecular weight glutenin subunits [HMW-GS] and low-molecular weight glutenin subunits [LMW-GS]). The IgE cross-reactivity of the sera was examined from one IHHWP patient with the extracts of one HWP preparation and UWP. Finally, the relative molecular size distributions of two HWP preparations (one the product of acid hydrolysis with a low degree of deamidation and the other the product of enzymatic hydrolysis) was characterized, and the binding of IgE in the serum of one IHHWP patient was determined using the separated polypeptide fractions of two HWP preparations.

The results showed reactivity of serum IgE from the IHHWP patients, especially with the albumins/globulins fraction and less so with the gliadins and LMW-GS fractions, but not with the HMW-GS fraction of UWP. Reactivity of serum IgE from one of the IHHWP patients was observed with the ω5-gliadin of UWP; this patient distinctly exhibited exercise-induced allergic reactions (urticarial) to ingestion of HWP in processed foods. Reactivity of serum IgE from the CO-WDEIA patient was observed with ω5-gliadin and LMW-GS fractions, but not with the HMW-GS fraction of UWP.

Binding patterns of serum IgE from the IHHWP patients to HWP preparations varied by IHHWP patient and by HWP preparation, but in no case did the IgEs bind to HWP polypeptides less than 30 kDa. The binding of serum IgE to UWP or to the albumins/globulins fraction of UWP was partially inhibited by HWP. However, the binding of serum IgE to HWP was almost completely inhibited by UWP or HWP. Based on these results, the authors suggested that almost all of the epitopes in the HWP preparation tested were also available in UWP. The molecular-size profiles of two of the HWP preparations ranged from <5 kDa to >1,000 kDa, and both preparations contained substantial amounts of high molecular-weight constituents. Binding of IgE in the serum of the IHHWP patient was greatest to the highest molecular-weight fractions of both of these HWP preparations (400 kDa to 1,000 kDa), weaker to intermediate molecular-weight fractions (30 kDa to 400 kDa), and faint or undetectable to the lowest molecular-weight fractions (<30 kDa).

Overall, the authors concluded that most IgE epitopes in UWP are conserved in HWP produced by industrial hydrolysis processes, and the production of new epitopes in the hydrolysates does not appear to contribute substantially to the differences in allergic responses in IHHWP patients compared with CO-WDEIA patients. Additionally, epitopes in UWP appear to be destroyed in HWP polypeptides less than about 30 kDa. Analysis of HWP fractions under non-reducing, non-dissociating conditions suggested that differences in allergic responses between IHHWP patients and CO-WDEIA patients may be attributable to hydrolysis-induced re-organization in HWP of epitopes that already exist in UWP; re-organization through entanglements, S-S bond interchanges, or non-covalent interactions among the HWP polypeptides may produce relatively soluble, high molecular-weight polypeptide aggregates that can present multiple epitopes efficiently to trigger allergic responses to HWP.

In a Japanese study, wheat protein hydrolysates that were produced by enzymatic hydrolysis had higher concentrations of peptides with molecular weights greater than 1,050 Da, compared with those produced by acid hydrolysis, which had extremely low concentrations of peptides with molecular weights greater than 1,050 Da. Investigation of the reactivity of these 2 types of hydrolysates revealed that the acid hydrolysates rarely inhibited IgE binding whereas enzymatic hydrolysates clearly inhibited the binding of IgE to wheat proteins. IgE of patients that had Type 1 hypersensitivity to HWP through percutaneous and/or rhinoconjunctival exposure to a facial soap containing HWP (40-50 kDa) reacted with high molecular weight polypeptide aggregates. However, an in vitro elicitation test using IgE from different categories of wheat-allergic patients (including patients sensitized to commercial HWP produced by acid hydrolysis, pediatric patients with food allergy to native wheat, adult patients exhibiting wheat-dependent exercise-induced anaphylaxis (WDEIA), and non-atopic healthy adults) revealed that
glutens acid-hydrolyzed to various extents retained the ability to activate mast cells in patients sensitized by exposure to commercial acid-hydrolyzed HWP.\(^{30}\) It is theorized that limiting the size of proteins or polypeptides to no more than approximately 30 amino acid residues (MW=3000 Da) would greatly reduce the potential for causing Type 1 reactions.\(^{26}\)

A study was performed comparing 5 Japanese women exhibiting both contact allergy (rhinocconjunctival reactions) to HWP (40-50 kDa) in a facial soaps and WDEIA reactions to eating “normal wheat products” such as bread, pasta, and pastries (referred to as HWP-WDEIA patients) with 18 Japanese women exhibiting CO-WDEIA reactions.\(^{31}\) The authors distinguished the 5 Japanese HWP-WDEIA patients from European patients exhibiting IHHWP (see study above), some of whom also exhibited allergic reactions to foods containing HWP, but none with allergic reactions to eating “normal wheat products.”

Positive skin prick tests were obtained for HWP in all 5 of the HWP-WDEIA patients, in contrast to the CO-WDEIA patients. Sera from HWP-WDEIA patients exhibited statistically-significantly elevated IgE reactivity with HWP, compared to reactivity with each of the wheat-protein fractions (i.e., albumins/globulins, gliadins, and glutenins). In contrast, sera from CO-WDEIA patients exhibited statistically-significantly elevated reactivity with the gliadins fraction of wheat proteins, compared to reactivity with HWP.

Sera from the HWP-WDEIA patients exhibited statistically-significantly elevated IgE reactivity with HWP, gluten, wheat flour, and each of the wheat-protein fractions, and statistically-significantly reduced reactivity with recombinant \(\omega_5\)-gliadin, compared to sera from CO-WDEIA patients. Based on these results, the authors suggested that sensitization of HWP-WDEIA patients to components of the gliadins fraction other than \(\omega_5\)-gliadin may help explain the elevated reactivity of sera from HWP-WDEIA patients with the complete gliadins fraction.

Pre-incubation of sera from HWP-WDEIA patients with HWP completely inhibited IgE reactivity with wheat extracts, but pre-incubation with wheat extracts did not inhibit reactivity with HWP. Conversely, pre-incubation of sera from CO-WDIEA patients with HWP only weakly inhibited reactivity with wheat extracts, while pre-incubation with wheat extracts strongly inhibited reactivity with HWP. Based on these results, the authors suggested that the reactivity of sera from CO-WDEIA patients with HWP is attributable to IgE epitopes that survive the hydrolysis of wheat proteins.

Overall, the authors concluded: (1) HWP-WDEIA is a clinical phenotype distinct from CO-WDEIA, as well as from the contact sensitivity to HWP observed in European patients that do not exhibit sensitivity to ingesting “normal wheat products,” (2) the use of a facial soap containing HWP caused both primary contact dermal / rhinoconjunctival sensitization to HWP and, secondarily, WDEIA sensitization to ingested wheat proteins in the HWP-WDEIA patients, and (3) sensitization to gliadins other than \(\omega_5\)-gliadin (e.g., \(\omega_1\)-gliadin and \(\gamma\)-gliadin) may be more important than sensitization to \(\omega_5\)-gliadin in the pathogenesis of HWP-WDEIA, compared with the pathogenesis of CO-WDEIA.\(^{31}\)

In another study, the allergic reactions of a group of Japanese patients diagnosed with HWP-WDEIA were found likely to have been sensitized primarily through percutaneous and/or rhinoconjunctival exposures to HWP (acid-hydrolyzed UWP; 40-50 kDa) in a facial soap.\(^{25}\) The authors noted that, by 2010, more than 1300 patients who used the soap exhibited facial angioedema after use, tested positive for sensitivity to the HWP in skin-prick tests and positive for serum IgE reactivity with the HWP, and developed WDEIA reactions in response to eating natural UWP. Angioedema predominated in the HWP-WDEIA patients, especially angioedema of the eyelids, in contrast to the urticarial wheals predominating in CO-WDEIA patients. The onset of allergic reactions in the HWP-WDEIA patients typically was 1 month to 5 years after starting to use the soap. Many of these patients developed WDEIA in response to eating wheat food products at about the same time as, or subsequent to, the onset of urticarial reactions to the soap.

About half of the HWP-WDEIA patients tested positive in skin-prick tests for sensitivity to wheat and bread. Almost all of the HWP-WDEIA patients tested positive in skin-prick tests for sensitivity to solutions of the soap or the HWP in the soap, in contrast to CO-WDEIA patients, none of whom exhibited sensitivity to these solutions. Only about 7% of HWP-WDEIA patients exhibited serum IgE reactivity with \(\omega_5\)-gliadin, compared to 80% of CO-WDEIA patients. Reactivity with \(\omega_5\)-gliadin among the few positive HWP-WDEIA patients was substantially weaker than the corresponding reactivity among the CO-WDEIA patients. About 17% of HWP-WDEIA patients exhibited serum IgE reactivity with \(\omega_5\)-gliadin and/or HMW-GS, compared to about 94% of CO-WDEIA patients. On the other hand, 70% or more HWP-WDEIA patients exhibited serum IgE reactivity with wheat protein or gluten, compared to only 30% to 40% of CO-WDEIA patients. Sera from HWP-WDEIA patients exhibited IgE binding to HWP polypeptides and to water-soluble and water-insoluble constituents of UWP, but not to purified \(\omega_5\)-gliadin. In comparison, serum IgE from CO-WDEIA patients bound to \(\omega_5\)-gliadin, as well as to the water-soluble and water-insoluble constituents of UWP, but not to the polypeptides of the HWP preparation. Pre-incubation of sera from the HWP-WDEIA patients with solutions of the HWP preparation resulted in concentration-
dependent inhibition of the binding of IgE to HWP polypeptides. HWP, but not purified ω5-gliadin, up-regulated the CD203c (an ecto-enzyme on the cell membranes of basophils and mast cells) in HWP-WDEIA patients. However, ω5-gliadin, but not the HWP, up-regulated CD203c in cells from CO-WDEIA patients.

The authors suggested that (1) the hydrophilic constituents of HWP may play an important role in percutaneous and/or rhinoconjunctival sensitization to HWP, (2) production of HWP by acid hydrolysis of UWP will yield charged terminal amino- and carboxyl-groups that increase the water solubility of the HWP, compared to that of UWP, and (3) the surfactants in a soap product will likely facilitate the dermal penetration of the HWP polypeptides, and thereby help to increase the likelihood of sensitization through percutaneous/rhino-conjunctival exposures in people using such products.8

Recommendations have been made to individuals with known protein hypersensitivity to minimize dermal exposure to botanical ingredients such as HWP and to not use products that have these constituents and can be incidentally inhaled.32 Additionally, it has been recommended that manufacturers of personal care products not use known or suspected allergens (including constituents of plants known to produce Type I hypersensitivity reactions or of plants that are in the same phylogenetic families as these plants) in products that may be incidentally inhaled (e.g., sprays, shampoos or shower gels, and, presumably, loose powder products as well).

Phototoxicity

No published phototoxicity studies on HWP and hydrolyzed wheat gluten were identified by a literature search for these ingredients and no unpublished data were submitted.

CASE STUDIES

A case of WDEIA in a non-atopic 40-year-old woman was reported in Japan.8 The patient developed facial wheals and nasal discharge while using an HWP- (Glupearl 19S-) containing facial soap (Cha no shizuku) over the course of a year (HWP = 40-50 kDa). Additionally, she suffered multiple episodes of eyelid edema after eating bread or while working or walking during an 11-month period prior to diagnosis. Skin prick tests were positive with a solution of the soap or the HWP, but negative with wheat or bread. The patient also tested positive for WDEIA after ingesting wheat and aspirin together (aspirin, like exercise, is a well-known trigger of allergic reactions). SDS-PAGE and western blotting analyses showed that serum IgE from this patient reacted with polypeptides ranging from 15 to 250 kDa in the HWP preparation and with both the water-soluble and water-insoluble fractions of UWP, but not with ω5-gliadin.

An additional 3 cases of WDEIA were reported by the same researchers in Japan.33 The 3 female patients had used the same brand of soap that contained HWP (40-50 kDa). Skin prick tests revealed positive reactions to a 0.1% solution of the soap in physiological saline and to 0.1% HWP in physiological saline. Western blotting of the patients’ sera IgE yielded positive reactions with the HWP. The researchers concluded that WDEIA was attributable to cross reactivity to wheat protein induced by HWP exposures in these patients.

A 51-year-old Japanese woman had been using a facial soap containing HWP (40-50 kDa) daily for several years.34 Approximately 3 months after she started to use the soap, she began to develop angioedema on the eyelids and urticarial rash on the face. She experienced similar episodes many times over a 5-year period when eating wheat-containing food followed by mild exercise, with clinical signs limited to her face. Five years after her initial use of the soap containing HWP, she had an anaphylactic reaction after ingesting normal wheat products and was suspected of having WDEIA. She had no history of atopic dermatitis, food hypersensitivities, or dry skin. The patient developed eyelid angioedema, dyspnea, and a generalized urticarial rash on her entire upper extremity following a skin prick test with the HWP from the soap diluted 1:10,000. An IgE test for wheat and gluten yielded 0.36 UA/ml and 0.40 UA/ml, respectively. Serum ω5 gliadin-specific IgE antibody titers were within normal limits. The patient did not have a mutation in human filaggrin (FLG), a defect that may disrupt skin barrier function.

In another case study, a 42-year-old woman reported an intense burning sensation over her face, neck, and scalp several hours after applying a moisturizing cream that contained HWP.35 Specific chemical characteristics of the HWP were not provided. Patch testing with the diluted ingredients of the moisturizing cream resulted in a positive reaction (D2+, D4+) to 50% aq. HWP. No reactions were observed from skin prick testing to standardized wheat extract or contact-urticaria testing with HWP.

Contact urticaria was reported in a 46-year-old woman.36 The patient developed the clinical signs after applying an eyelid cream and a body moisturizer that contained HWPs 3 months prior to consulting her physician. Strong positive reactions were observed from the preserved food, wheat gluten that was in the food, the cosmetic creams, and HWP in open application tests and skin prick tests. Further investigation revealed that the HWPs in the
cosmetic creams were from the same manufacturer as the gluten in the preserved food. Specific chemical characteristics of the HWP were not provided.

A 27-year-old woman was reported to have a pruritic, erythematous, urticarial rash that became increasingly more intense after subsequent use of a moisturizing body cream that contained HWP. The wheat hydrolysate was not characterized in this study. Skin prick tests with common inhalant allergens, natural rubber latex, and cereal grains, including wheat, were negative. Also negative were the results of prick tests with a series of 21 protein allergens from plant and animal sources that included hen’s egg, cow’s milk, milk casein, almond, silk protein, aloe gel, papaya fruit, and hydrolyzed collagen. Total serum IgE was slightly elevated. The individual components of the body cream tested negative in an open application test, but a skin prick test was positive (8 mm) to HWP. Further IgE testing revealed that binding occurred specifically to wheat hydrolysate.

In another case study, a 64-year-old woman was reported to have itchy, erythematous, edematous lesions on the eyelids, face, and neck following use of a moisturizing cosmetic cream. The patient was patch tested with the (GEIDC) standard and cosmetics series, the cosmetic cream, and the individual ingredients of the cream. Positive reactions (+++) were observed to nickel sulfate, the cosmetic cream (tested neat), and to the HWP ingredient of the cream (10% aq.). Open testing with the HWP (10% aq.) was negative at 30 min. Specific chemical characteristics of the HWP were not provided.

A 23-year-old man with no history of atopy was reported to have a rash that occurred immediately after application of a face cream. The rash included highly pruritic wheals on the face and neck accompanied by bilateral palpebral edema. Other systemic symptoms were not observed. The patient reported a similar reaction previously to a sunscreen and did not report food-induced symptoms or intolerance. A nonblinded skin test with the face cream was negative. Patch testing with the cosmetics True Test panel and the patient’s own personal care products resulted in a positive (++) reaction to the patient’s face cream at 48 and 96 h; all other readings were negative. Patch testing with the components of the face cream resulted in a positive (++) reaction to 1% HWP in water at 48 and 96 h. Testing in 10 control subjects yielded negative results. The patient underwent further prick tests with flours and cereals, with positive results reported for malt (5 x 4 mm), cereal mix (7 x 5 mm), oats (5 x 5 mm), and hydrolyzed wheat extract (18 x 14 mm). Total IgE was 136 U/ml (reference range = 1-100 U/ml). Results of specific IgE testing to buckwheat, rice, oats, barley, rye, corn, common millet, soy, and wheat were negative. Specific chemical characteristics of the HWP were not provided.

In a case study of a 3-year-old girl with a history of moderate atopic dermatitis, eczema-like skin eruptions were observed following use of an emollient containing HWP. Scaly erythematous lesions were observed on her knees. No evidence of contact urticaria was observed. Closed patch tests with the European standard series and the emollient were positive (+) for the emollient on days 2 and 3. Additional patch tests with the individual components of the emollient yielded positive results (++) for palmitoyl HWP on days 2 and 3. Prick test, open test, and open patch test for palmitoyl HWP were negative, as were prick test and radioallergosorbent test with wheat. Specific chemical characteristics of the HWP were not provided.

**SUMMARY**

Hydrolyzed wheat gluten and HWP function primarily as skin and hair conditioning agents in personal care products. These protein derivatives are prepared by subjecting wheat proteins to enzymatic or other chemical, partial hydrolyses.

HWP has the most reported uses in cosmetic and personal care products, with a total of 1077; approximately half of those uses are in non-coloring hair products. Hydrolyzed wheat gluten has 78 reported uses, with about half of the uses reported to be in hair tints.

In the Council’s use concentration survey, HWP had a wide maximum use concentration range of 2.0 x 10⁻⁵ to 1.7%, with the 1.7% reported in rinse-off non-coloring hair products. Hydrolyzed wheat gluten had a maximum use concentration range of 0.005% to 0.09%, with the 0.09% reported in eye makeup preparations.

The FDA determined the use of peptones as direct food substances are GRAS.

Ocular and dermal irritation studies of HWP found this ingredient not to be a significant irritant. HRIPT studies of HWP concluded that this ingredient was not a dermal irritant during induction or sensitizers during challenge.

Multiple cases of allergic reactions, including Type 1 hypersensitivity reactions, were reported in individuals who had used personal care products that contained HWP, most of which were to a facial soap in Japan that contained HWP of 40-50 kDa in size. Several studies have been conducted to characterize the cause, manifestations, and mechanisms of these reactions, including tests of serum IgE binding and reactivity wheat protein, wheat protein fractions, and HWP and hydrolyzed gluten prepared using acid- and/or enzymatic-hydrolysis methods yielding products with varied polypeptide size profiles.
DISCUSSION

The hydrolyzed wheat protein and hydrolyzed wheat gluten discussed in this safety assessment are polypeptides ranging from approximately 4 amino acids (approximately 500 Da) to over 220 amino acids (over 30 kDa) in length. Peptides greater than 30 amino acids in length can precipitate Type I hypersensitivity reactions by enabling the crosslinking of IgE in individuals sensitized to hydrolyzed wheat protein or hydrolyzed wheat gluten. Traditional human repeat insult patch tests and related tests do not detect Type I reactions. The Panel felt the data on the elicitation of Type I hypersensitivity reaction in sensitized individuals were adequate to support the safety of hydrolyzed wheat gluten and hydrolyzed wheat protein ingredients with peptide length distributions that do not exceed 30 amino acids. However, no data were available to determine a peptide-length threshold below which sensitization would not be induced in people who are not already sensitized to hydrolyzed wheat gluten or hydrolyzed wheat protein. The Panel noted that a study of mice with tape-stripped skin demonstrated the induction of sensitization to a hydrolyzed wheat protein preparation with a size distribution ranging from about 40 kDa to 50 kDa (or approximately 360-450 amino acids in length). The Panel also noted reports indicating that people using cosmetic products containing hydrolyzed wheat proteins applied to the eye area were sensitized. Unless data can be produced that demonstrate a size-distribution threshold below which sensitization cannot be induced, cosmetics containing hydrolyzed wheat gluten and hydrolyzed wheat protein should not be used on damaged skin or on mucous membranes. These ingredients should also not be used in products that may be inhaled, including spray products.

The Panel discussed the issue of incidental inhalation exposure from aerosol and pump hair spray products. No inhalation data were available. These ingredients reportedly are used at maximum concentrations up to 0.5% in cosmetic products that may be aerosolized.

The Panel also expressed concern regarding pesticide residues and heavy metals that may be present in botanical ingredients. They stressed that the cosmetics industry should continue to use the necessary procedures to limit these impurities in the ingredient before blending into cosmetic formulation.

The Panel asked that the cosmetics industry continue to provide additional data on manufacturing practices, characterization methods, and composition, including peptide size distributions, to enable better characterization of the nature and variability of these ingredients as used in cosmetic products and to enable the Panel to refine its conclusion.

CONCLUSION

The CIR Expert Panel concluded that hydrolyzed wheat gluten and hydrolyzed wheat protein are safe in cosmetics when formulated to minimize peptide lengths greater than 30 amino acids (approximately 3.3 kDa). Additionally, these ingredients should not be used on damaged skin or in products that may come into contact with mucous membranes or may be incidentally inhaled.
Tables

Table 1. Definitions and functions of the ingredients in this safety assessment. (The italicized text below represents additions made by CIR staff.)

<table>
<thead>
<tr>
<th>Ingredient CAS No.</th>
<th>Definition</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrolyzed Wheat Gluten 100684-25-1</td>
<td>Hydrolyzed Wheat Gluten is the partial hydrolysate of Triticum Vulgare (Wheat) Gluten derived by acid, enzyme or other method of hydrolysis.</td>
<td>Hair Conditioning Agent; Skin-Conditioning Agent-Misc.</td>
</tr>
<tr>
<td>Hydrolyzed Wheat Protein 70084-87-6 100209-50-5 222400-28-4</td>
<td>Hydrolyzed Wheat Protein is the partial hydrolysate of wheat protein derived by acid, enzyme or other method of hydrolysis.</td>
<td>Film formers; Hair Conditioning Agent; Skin-Conditioning Agent-Misc.</td>
</tr>
</tbody>
</table>

Table 2. Summary of information from suppliers of hydrolyzed wheat protein.*

<table>
<thead>
<tr>
<th>Source</th>
<th>Method of Manufacture</th>
<th>Molecular Weight</th>
<th>Nitrogen Content</th>
<th>Gluten Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 product defatted wheat germ</td>
<td>3 products enzyme hydrolysis</td>
<td>1 product average MW = 350 Da</td>
<td>1 product 12-15% nitrogen</td>
<td>1 product “gluten-free”</td>
</tr>
<tr>
<td></td>
<td>1 product alkaline and enzyme hydrolysis</td>
<td>1 product average MW = 2200 Da</td>
<td></td>
<td>1 product &lt; 100 ppm gluten</td>
</tr>
</tbody>
</table>

* Information includes data summarized in Anonymous, 2012.13

Table 3. Frequency and concentration of use for plant- and animal-derived hydrolyzed proteins according to duration and type of exposure.16,17

<table>
<thead>
<tr>
<th>Hydrolyzed Wheat Gluten</th>
<th>Hydrolyzed Wheat Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td># of Uses</td>
<td>Conc. of Use (%)</td>
</tr>
<tr>
<td>Totals*</td>
<td>78</td>
</tr>
<tr>
<td>Leave-On</td>
<td>13</td>
</tr>
<tr>
<td>Rinse Off</td>
<td>62</td>
</tr>
<tr>
<td>Diluted for (Bath) Use</td>
<td>3</td>
</tr>
<tr>
<td>Eye Area</td>
<td>1</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Inhalation-Sprays</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Inhalation-Powder</td>
<td>1</td>
</tr>
<tr>
<td>Dermal Contact</td>
<td>26</td>
</tr>
<tr>
<td>Deodorant (underarm)</td>
<td>NR</td>
</tr>
<tr>
<td>Hair - Non-Coloring</td>
<td>17</td>
</tr>
<tr>
<td>Hair-Coloring</td>
<td>35</td>
</tr>
<tr>
<td>Nail</td>
<td>NR</td>
</tr>
<tr>
<td>Mucous Membrane</td>
<td>15</td>
</tr>
<tr>
<td>Baby Products</td>
<td>3</td>
</tr>
</tbody>
</table>

* Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.
NR = none reported
*0.03-0.05% in aerosol hair sprays; 0.0003-0.5% in pump hair sprays; and 0.002-0.02% in spray tonics, dressings, and other hair grooming aids.
References


24. AMA Laboratories Inc. 2006. 50 human subject repeat insult patch test sin irritation/sensitization evaluation (occlusive patch). Hydrolyzed Wheat Protein. AMA Ref. No.: MS06.RIPT.K9014O.50.SEI. Unpublished data submitted by the Personal Care Products Council.


